Longevity Clinic Software: The Requirements Checklist

The pages that ranked for “longevity clinic software” when we checked on October 29, 2026 were a vendor product page, a vendor blog on what to test in an EMR trial, and a vendor blog on the longevity tech stack. Each listed features such as lab ordering, e-prescribing, memberships, consents, and audit logs, and none tied a feature to the rule that creates it. That leaves a physician or nurse practitioner opening a hormone, peptide, or longevity practice with a wish list and no way to tell which features exist because a regulation requires them. Several of those rules carry hard numbers: DEA requires electronic controlled-substance prescribing software to authenticate the prescriber with two of three factors and to be audited by a third party every two years or on any functionality change, CLIA certificates are generally effective for two years, the DEA’s telemedicine flexibilities for controlled substances run through December 31, 2026, and New York’s auto-renewal statute sets civil penalties of $100, $500, and $1,000 depending on the violation.

This guide writes the requirements list from the compliance stack instead. Each requirement is tied to the rule that creates it, and each section ends with a question to ask in the vendor demo. It covers what the ranking pages skip: board charting standards for hormone and peptide protocols, CLIA for in-house lab tests, EPCS for testosterone, the 503A rules that decide whether a compounded peptide can be ordered at all, per-administration lot records, membership auto-renewal law, and the HIPAA safeguards behind the portal and the audit log.

It is vendor-free on purpose. You leave with a demo script, not a ranking, and nothing here is legal advice. Where a rule is a single state’s, the post says so. Current as of October 2026.

What does longevity clinic software actually have to do?

Eight rule sets drive the requirements. The table maps each to the capability it forces and the question that exposes whether a vendor has it.

Requirement Rule behind it What to ask the vendor
Protocol charting for hormone and peptide plans Fla. Admin. Code 64B8-9.003 (one state’s example); Cal. Bus. & Prof. Code 2266 Can I see every dose change for one patient, dated, with the reason?
Labs, results, and recurring monitoring 42 CFR 493.3; 42 CFR 493.15 Which certificate does each in-house result belong to, and does a prescription create a lab task?
eRx, EPCS, and compounded orders to 503A pharmacies 21 CFR 1311.115; 21 U.S.C. 353a Which two factors, whose audit, and which compounder filled this order?
Inventory with lot and expiration per administration Fla. Admin. Code 64B8-9.003(4) (one state’s example); 21 U.S.C. 353b Pick a lot number and show me every patient who received it.
Memberships and auto-renewal N.Y. Gen. Bus. Law 527-a (one state’s example) Is cancellation as easy as sign-up, and is every attempt timestamped?
Portal, messaging, and video telehealth 45 CFR 164.312 Do video visits write to the same chart, under the same BAA?
Consent for compounded or unapproved products FDA, on compounded drugs Where does the signed consent live, and is it tied to the product?
Audit logs and BAAs 45 CFR 164.308 Show me who opened this chart, and which components your BAA covers.

The sections below take these one at a time.

How should software chart a hormone or peptide protocol?

A testosterone titration or a peptide cycle is a series of dated dose decisions, and boards write their record standards in those terms. Florida’s rule on standards for adequacy of medical records (Fla. Admin. Code 64B8-9.003, one state’s example) says the record “shall contain sufficient information to identify the patient, support the diagnosis, justify the treatment and document the course and results of treatment accurately,” including at a minimum patient histories, examination results, test results, and records of drugs prescribed, dispensed, or administered. The same rule requires sufficient detail to clearly demonstrate why the course of treatment was undertaken, accurately dated entries, and late entries clearly labeled as late and dated when entered.

California reaches the same place by a different route. Business and Professions Code 2266 says a physician’s failure to maintain adequate and accurate records of services to patients constitutes unprofessional conduct, and the section sets a minimum retention of seven years after the last date of service to a patient. Other boards phrase these duties differently, so verify yours.

Labeling also moves. On February 28, 2025, FDA recommended class-wide changes to testosterone labels: adding the TRAVERSE trial results, removing the Boxed Warning language about increased risk of adverse cardiovascular outcomes, retaining the Limitation of Use for age-related hypogonadism, and adding a warning about increased blood pressure to products that lacked one. A protocol template that cannot be edited and dated will go stale.

Telehealth visits carry the same standard. Under Fla. Stat. 456.47(3), a telehealth provider “shall document in the patient’s medical record the health care services rendered using telehealth according to the same standard as used for in-person services.”

The EHR therefore has to hold each hormone or peptide plan as a dated series of orders and dose changes, each with a documented reason, keep late entries labeled as late, and let the clinic edit protocol templates as labeling changes. Ask the vendor: open one patient and show me every dose change in order, with who made it, when, and why.

What does CLIA require of a clinic that runs its own labs?

A longevity practice is built on biomarkers, and the rule changes the moment a test is run in the building. Under 42 CFR 493.3(a), a laboratory is cited as out of compliance with section 353 of the Public Health Service Act unless it holds a current certificate of waiver, registration certificate, certificate of compliance, or certificate of accreditation, or is CLIA-exempt. The listed exceptions are forensic-only testing, research laboratories that do not report patient-specific results, and SAMHSA-certified drug testing.

CMS’s brochure on obtaining a certificate of waiver says CLIA “generally requires all facilities that perform even one applicable test, including waived tests,” on materials derived from the human body for the purpose of diagnosis, prevention, or treatment of disease, or assessment of health, to meet federal requirements. All certificate types “are generally effective for two years,” and a Certificate of Waiver is issued to a laboratory that performs only waived tests. FDA determines which tests are waived. The brochure also notes that New York and Washington operate their own laboratory programs.

Waived tests are simple examinations that are cleared by FDA for home use, use methodologies so simple and accurate that erroneous results are negligible, or pose no reasonable risk of harm if performed incorrectly (42 CFR 493.15(b)), and a laboratory with a certificate of waiver must follow the manufacturer’s instructions (493.15(e)). FDA categorizes tests as waived, moderate, or high complexity, and tests not yet categorized default to high complexity. A fingerstick or urine test run at the front desk therefore makes the clinic a CLIA laboratory.

The recurring monitoring tasks come from labeling. One example is the AZMIRO (testosterone cypionate) prescribing information, revised 7/2025. It is a single product’s label, so check the labeling for the product you prescribe.

Label point What the label says
Before starting (Dosage and Administration 2.2) Confirm the diagnosis by ensuring serum testosterone concentrations have been measured in the morning on at least two separate days
Before starting (Warnings and Precautions 5.1) “Check that hematocrit is not elevated prior to initiating AZMIRO.”
During treatment (5.1) “Periodically monitor hematocrit levels during treatment.”
If hematocrit becomes elevated (5.1) Stop until it decreases to an acceptable concentration; if restarting again elevates hematocrit, stop permanently

The EHR therefore has to order and store lab results, record which tests were run in-house and under which certificate, keep send-out and in-house results in one trend, and turn a prescription date into recurring monitoring tasks. Ask the vendor: if I start a patient on a labeled therapy that requires periodic hematocrit, what task does the system create, and how do I see who is overdue?

Does a longevity clinic need EPCS?

Testosterone is a Schedule III controlled substance (drug code 4000) and phentermine is Schedule IV (drug code 1640) on DEA’s alphabetical list, with the schedules set at 21 CFR 1308.13 and 1308.14. A clinic that prescribes testosterone is therefore in controlled-substance territory, and our post on the DEA telemedicine rule and TRT covers the schedule and the telemedicine timeline.

Federally, under 42 CFR 423.160, prescribers must conduct at least 70 percent of their Schedule II through V prescriptions that are Part D drugs electronically. Exempt are prescribers issuing 100 or fewer controlled-substance Part D prescriptions per year, prescribers in emergencies, and prescribers with CMS waivers. A purely cash-pay clinic with no Medicare patients is not bound by that mandate. State mandates are what reach cash-pay prescriptions, and they differ. Three examples:

State Rule What it says
Florida Fla. Stat. 456.42(3) A prescriber who maintains a system of electronic health records “may only electronically transmit prescriptions for such drugs,” with eight exceptions, including a prescriber and dispenser that are the same entity, a department waiver not to exceed 1 year, impracticality for the patient, and documented price comparison
New York Pub. Health Law 281 “no person shall issue any prescription in this state unless such prescription is made by electronic prescription,” with exceptions including temporary technological failure, waivers, and impracticality for the patient (a controlled-substance quantity under that exception cannot exceed a five-day supply); a practitioner who certifies no more than twenty-five prescriptions in a twelve-month period is not required to e-prescribe; the page carries the note “NB Repealed June 1, 2029.”
Texas Health & Safety Code 481.074(b) Bars dispensing or administering a controlled substance without an electronic prescription, subject to the exceptions in 481.0755, which lists eleven circumstances including when the prescriber and dispenser are in the same location or under the same license

When you do send controlled prescriptions electronically, DEA sets conditions on the software. Under 21 CFR 1311.115, the application must require the practitioner to authenticate with two of three factors: something you know, something you are, or something you have. A hard token must be separate from the computer it gains access to and meet at least FIPS 140-2 Security Level 1. Under 21 CFR 1311.300, the application provider must have a third-party audit before the application is used for controlled-substance prescriptions, and again whenever controlled-substance functionality is altered or every two years, whichever occurs first. The audit must be by a person qualified to conduct a SysTrust, WebTrust, or SAS 70 audit, or a Certified Information System Auditor.

The EHR therefore has to support two-factor signing for Schedule III prescriptions and rest on a current Part 1311 audit, and it has to handle your state’s exceptions as documented events rather than free text. Ask the vendor: which two factors does signing use, whose audit covers the EPCS function (yours or a third party’s), and what were its date and scope?

How do compounded hormone and peptide orders reach a 503A pharmacy?

A compounded product is ordered for a person, and the statute says so. The 503A exemption applies to a drug compounded “for an identified individual patient based on the receipt of a valid prescription order or a notation, approved by the prescribing practitioner, on the prescription order that a compounded product is necessary for the identified patient” (21 U.S.C. 353a(a)).

The pharmacy must also be able to lawfully use the ingredient. Under 21 U.S.C. 353a(b)(1)(A), each bulk drug substance must comply with an applicable USP or NF monograph if one exists. If no monograph exists, the substance must be a component of a drug approved by the Secretary. If neither applies, it must appear on a list developed by the Secretary through regulations, the 503A bulks list. A compounder may also not compound a product that appears on the Federal Register list of drugs withdrawn or removed as unsafe or not effective (353a(b)(1)(C)).

The EHR therefore has to route a patient-specific order to the compounding pharmacy, record which compounder filled it, and store the substance name as the compounder labels it. Ask the vendor: show me a compounded order that names the patient, carries the prescription, and records the pharmacy that filled it.

What does inventory tracking need for injectables and peptides?

Two questions arise: what must the record hold at the moment of administration, and what is the legal status of the substance in the vial.

The administration record

Florida’s rule is the clearest primary source on per-administration capture, and it is one state’s example. Rule 64B8-9.003(4) says medical records in which compounded medications are administered to a patient in an office setting must contain, at a minimum:

Element Florida 64B8-9.003(4)
(a) The name and concentration of medication administered
(b) The lot number of the medication administered
(c) The expiration date of the medication administered
(d) The name of the compounding pharmacy or manufacturer
(e) The site of administration on the patient
(f) The amount of medication administered
(g) The date medication administered

A 503B outsourcing facility’s label must carry, among other things, the lot or batch number, the date compounded, the expiration date, and storage and handling instructions (21 U.S.C. 353b(a)(10)). That is a labeling duty on the facility, not a recordkeeping rule for the clinic; the practical consequence is traceability, because an inventory that captures the same lot and expiration data can trace a recall or a beyond-use question to the patients who received that lot.

A clinic that dispenses for a fee takes on more. Under Fla. Stat. 465.0276(2), a practitioner who dispenses medicinal drugs for human consumption for fee or remuneration must register with the professional licensing board as a dispensing practitioner, comply with all laws and rules applicable to pharmacists and pharmacies, and give the patient a written prescription before dispensing. Our nurse practitioner checklist covers dispensing registration.

For controlled substances held in the office, such as testosterone, DEA adds its own records:

DEA record element Rule
Each dispense records units or volume, the name and address of the person receiving it, the date, and the name or initials of the person who dispensed or administered it 21 CFR 1304.22(c)
Records kept at least 2 years and available for inspection 21 CFR 1304.04(a)
Initial inventory on the day the registrant first dispenses 21 CFR 1304.11(b)
New inventory at least every two years 21 CFR 1304.11(c)

Our compounded GLP-1 post carries an inventory table (lot, expiration, beyond-use date, date received and source, license verification, storage, date opened, administration record tied to lot, order in the chart, disposal) that applies equally here.

The status of the peptide in the vial

For peptides, the second question can decide whether the product can be ordered at all. Section 353a(b)(1)(A), above, means a substance with no USP monograph that is not a component of an approved drug and is not on the 503A bulks list cannot lawfully be compounded under 503A. Where FDA has not acted, its interim policy categories decide its enforcement posture. On its 503A bulk drug substances page (content current as of May 14, 2026), FDA says it “does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1” provided the guidance conditions are met. For Category 2, FDA “has identified significant safety risks relating to the use of these substances in compounding pending further evaluation,” and “FDA would consider taking action against a compounder” under its general enforcement policies. Category 3 holds substances “nominated with insufficient supporting information for FDA to evaluate them,” with the same enforcement posture as Category 2. The page adds that the agency “does not intend to place bulk drug substances nominated on or after January 7, 2025, into these categories.”

FDA’s page on bulk drug substances that may present significant safety risks (content current as of April 22, 2026) states that such substances “have been placed in category 2 under the interim policies.” Its Category 2 entries relevant to this segment include the following.

Substance Entry and date FDA note
Ipamorelin acetate 503B, September 29, 2023 Cites a published study identifying “serious adverse events including death when ipamorelin was administered intravenously”
GHRP-2 503B, September 29, 2023
GHRP-6 503B, September 29, 2023
Ibutamoren mesylate 503A, September 29, 2023; 503B, December 29, 2022 “potential for congestive heart failure in certain patients”
Kisspeptin-10 503A, September 29, 2023
Tranilast 503B, September 29, 2023

A second table on the same page, headed “Bulk drug substances nominated but withdrawn,” is introduced by this sentence: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.” It lists AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu (injectable routes), ipamorelin acetate, KPV, PEG-MGF, melanotan II, MOTs-C, selank, semax, thymosin alpha-1, and thymosin beta-4 fragment (TB-500). The page gives no removal dates. Ipamorelin acetate appears in both tables.

Seven of those substances went before FDA’s Pharmacy Compounding Advisory Committee. A Federal Register notice published April 16, 2026 (91 FR 20465) set the July 23 to 24, 2026 meeting, at which the committee would discuss substances being considered for inclusion on the 503A bulks list: BPC-157, KPV, TB-500, and MOTs-C on July 23, and emideltide (DSIP), semax, and epitalon on July 24, each for the specific uses listed in the notice (BPC-157 for ulcerative colitis and MOTs-C for obesity and osteoporosis, for example). FDA’s briefing document for the meeting says that the nominations had been withdrawn by the nominator but that FDA was electing to proceed with the presentation to the committee. The meeting page (content current as of August 6, 2026) lists the agenda and materials. As of October 29, 2026, FDA has published no final decision, and a Federal Register search returns no rule or notice adding any of the seven substances to the 503A bulks list. A committee meeting is not a listing.

The EHR therefore has to record per product the substance name as the compounder labels it, the compounder, lot, expiration, and date opened, link each administration to a patient and a lot, and let you find and quarantine every vial of a substance when FDA’s categories move. For controlled substances it also has to produce the DEA dispensing elements and inventory counts on request. Ask the vendor: pick a lot number and show me every patient who received it, and show me where the compounder and the substance’s 503A status are recorded.

How do memberships and auto-renewal law apply?

Longevity programs are usually sold as recurring memberships, which puts the billing system under auto-renewal law. New York’s General Business Law 527-a (effective November 5, 2025, per our auto-renewal post) is one state’s example and a detailed one:

Requirement What 527-a says
Disclosure and consent Terms “in a clear and conspicuous manner” before consent is requested; no charge “without first obtaining the consumer’s affirmative consent”
Cancellation A “simple cancellation mechanism that is as easy to use as the mechanism” used to consent, through the same medium; for in-person consent, at least “an online mechanism or over a telephone number”
Price change Notice “at least five business days prior, but no more than thirty days prior”
Free trials longer than a month Notice “at least three days before but not more than twenty-one days before” the cancellation deadline
Penalty Up to $100 for a single violation and $500 for multiple violations from a single act; for a knowing violation, up to $500 and $1,000

Per our membership auto-renewal post, New York City’s click-to-cancel rule took effect October 1, 2026. It requires an online cancellation path even for in-person sign-ups, with restitution of every charge after a member’s first cancellation attempt and penalties of $525, $1,050, and $3,500. The FTC’s 2024 click-to-cancel rule was vacated by the Eighth Circuit on July 8, 2025, so state law governs today.

The EHR therefore has to offer cancellation at least as easy as sign-up, record when renewal and price-change notices were sent, and keep a timestamped cancellation log, because the NYC restitution clock runs from the first attempt. Ask the vendor: show me the cancellation log for a member who tried to cancel twice.

What must the patient portal, messaging, and telehealth satisfy?

A portal, a message thread, and a video visit are all systems that maintain electronic protected health information, so the HIPAA Security Rule’s technical safeguards at 45 CFR 164.312 apply to each. Access control under 164.312(a)(1) limits access to persons or software programs that have been granted access rights; unique user identification under (a)(2)(i) is Required (“Assign a unique name and/or number for identifying and tracking user identity”); audit controls under (b) must “record and examine activity in information systems that contain or use electronic protected health information”; person or entity authentication under (d) verifies that a person seeking access “is the one claimed”; and transmission security under (e)(1) guards ePHI “that is being transmitted over an electronic communications network.”

Video visits also have to write to the chart. Under the Florida telehealth statute, a telehealth provider has the duty to practice in a manner consistent with the prevailing professional standard of practice for a provider of in-person care (456.47(2)(a)) and must document telehealth services to the same standard as in-person ones. For controlled substances, the DEA and HHS extended the telemedicine flexibilities through December 31, 2026 (Fourth Temporary Extension, 90 FR 61301). Testosterone is Schedule III, so that date matters to a TRT practice, and our DEA telemedicine post tracks it.

The EHR therefore has to give each user a unique login, authenticate patients into the portal, apply transmission security to messaging and video, and write every telehealth encounter into the same chart as in-person care. It should also record, per patient, whether and when an in-person evaluation occurred. Ask the vendor: are video and messaging built in or third-party tools, and does your BAA cover them?

FDA states that the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. That fact is the reason consent for a compounded hormone or peptide is more than a signature line. No federal rule on this list specifies the form of the consent, but boards do require it to live in the record. Florida’s obesity-drug rule, 64B8-9.012(5), requires written informed consent from the patient and says a copy of the signed consent “shall be included in the patient’s medical record.” That rule concerns weight-loss drugs, not hormones or peptides, so treat it only as one state’s example of a board that requires the signed copy to live in the chart.

Our compounded GLP-1 post lays out seven consent elements: that the product is not FDA-approved and not reviewed, the documented reason for choosing it, who the compounder is, known risks including vial dosing errors, alternatives, how adverse events are reported through MedWatch, and state-required content. For a peptide, the documented-reason element becomes the 503A status of the substance, which is the category discussion in the inventory section above.

The EHR therefore has to capture a signed consent tied to the specific product and compounder, store it in the chart, and show which patients on a compounded or unapproved product have none on file. Ask the vendor: list every patient on a compounded product and whether a signed consent is on file for it.

What do audit logs and business associate agreements cover?

Audit logging is a stated requirement, not a nicety. Section 164.312(b) requires audit controls that record and examine activity in systems containing ePHI. The administrative safeguards at 45 CFR 164.308 add three duties. Information system activity review, 164.308(a)(1)(ii)(D), is Required: “Implement procedures to regularly review records of information system activity, such as audit logs, access reports, and security incident tracking reports.” Log-in monitoring, (a)(5)(ii)(C), is Addressable: “Procedures for monitoring log-in attempts and reporting discrepancies.” And under (b)(1) and (b)(3), a covered entity may permit a business associate to create, receive, maintain, or transmit ePHI only if it obtains satisfactory assurances, documented “through a written contract or other arrangement” that meets the requirements of 164.314(a).

Whether a cash-only practice is a covered entity depends on 45 CFR 160.103: a provider is a covered entity only if it transmits health information electronically in connection with a covered transaction. A cash-only practice that never does so may fall outside the definition, and the safer build is to assume coverage. Our weight loss requirements post walks through the covered-entity question, and our HIPAA form builder post covers the BAA and Security Rule detail.

The EHR therefore has to keep a reviewable log of who accessed or changed each record, support log-in monitoring, and sign a BAA that covers every component that carries patient information. Ask the vendor: show me who opened this chart in the last 30 days, and which components of your system are not covered by your BAA.

The requirements checklist and the demo questions

Use this table as the demo script.

Requirement Rule Demo question
Dated dose history with reasons Fla. Admin. Code 64B8-9.003 (example); Cal. B&P 2266 Every dose change for one patient, in order
Editable, dated protocol templates FDA testosterone labeling changes, February 28, 2025 Show me how a template change is versioned
Recurring lab tasks from a prescription Product labeling (example: AZMIRO 5.1) What task does a start date create?
In-house tests tied to a CLIA certificate 42 CFR 493.3; 493.15 Which certificate covers this result?
Two-factor EPCS signing 21 CFR 1311.115 Which two factors?
Third-party audit of the EPCS application 21 CFR 1311.300 Whose audit, date, and scope?
State EPCS exceptions documented Fla. Stat. 456.42; N.Y. PHL 281; Tex. H&S 481.074 (examples) How is an exception recorded?
Patient-specific compounded order with compounder recorded 21 U.S.C. 353a(a) Show the order and the pharmacy that filled it
Substance, compounder, and 503A status per product 21 U.S.C. 353a(b)(1)(A); FDA interim categories Find every vial of one substance
Lot and expiration per administration Fla. Admin. Code 64B8-9.003(4) (example); 21 U.S.C. 353b(a)(10) Trace one lot to patients
DEA dispensing record and inventory 21 CFR 1304.22, 1304.04, 1304.11 Controlled-substance dispensing report
Cancellation log and notice records N.Y. Gen. Bus. Law 527-a (example); our auto-renewal post Timestamped cancellation history
Portal, messaging, and video under unique logins 45 CFR 164.312 Are all three covered by the BAA?
Signed consent tied to the product FDA on compounded drugs; Fla. Admin. Code 64B8-9.012(5) (example) Patients on a compounded product with no consent on file
Reviewable audit log 45 CFR 164.312(b); 164.308(a)(1)(ii)(D) Who opened this chart this month

Four follow-ups to calendar from this post: the DEA telemedicine flexibilities for controlled substances end December 31, 2026; FDA has published no final decision on the seven peptides as of October 29, 2026, and its 503A bulks page is current as of May 14, 2026 while the Category 2 page is current as of April 22, 2026; New York Public Health Law 281 carries a repeal date of June 1, 2029; and the testosterone label used as the example here was revised 7/2025, after FDA’s February 28, 2025 class-wide labeling changes.

What a generic EHR will not do

A system built for fee-for-service visits tends to lack the structures this list requires: a per-lot administration record, a per-patient compounder and 503A-status field, a recurring monitoring task created by a prescription date, and a membership cancellation log. It may also route EPCS through a third party, in which case the question is whose Part 1311 audit covers the function and when it was done. None of that makes such a system a bad EHR for a visit-based practice. It means a longevity practice should test each gap on the checklist before signing, because the missing structure is the one an inspector, a recall, or a canceling member will ask about.


A longevity practice’s compliance stack runs through the chart: the protocol, the controlled-substance signature, the lot record, the consent, and the membership. PrismEHR for wellness and longevity practices includes charting with specialty templates for wellness consultations and longevity assessments, medication tracking and dosage adjustments, native e-prescribing with DEA-compliant EPCS, medication history and interaction checking, secure messaging and telehealth, a patient portal with two-way secure messaging, support for packages and subscriptions, longitudinal tracking of custom metrics, and a business associate agreement. Intake and consent forms can be built in CuratoForm. If you are also weighing the weight-loss side of the segment, read our requirements checklist for weight loss clinics, then run the checklist above against any system you are considering, ours included.